Advertisement
UK markets closed
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • CRUDE OIL

    78.57
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,322.10
    -9.10 (-0.39%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • Bitcoin GBP

    50,325.77
    -291.02 (-0.57%)
     
  • CMC Crypto 200

    1,309.54
    -55.58 (-4.07%)
     
  • NASDAQ Composite

    16,332.56
    -16.69 (-0.10%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics

Most biotechs don't have a diversified business model. Both 23andMe and Fulgent provide genetic testing and diagnostic services as well as perform drug development. The idea is that there's probably a competitive advantage of some kind in drug development, lurking somewhere in the reams of genetic information that the companies generate via their testing services.